Nektar Therapeutics (NKTR) has been beaten down lately with too much selling pressure. While the stock has lost 38.5% over ...

Shares of Nektar Therapeutics (NKTR) have been struggling lately and have lost 11.5% over the past four weeks. However, a ...

Nektar Therapeutics named Brian Kotzin its interim chief medical officer, succeeding Mary Tagliaferri, who stepped down from the role citing personal reasons. Kotzin will assist in the search for a ...

Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic ...

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers Squibb’s checkpoint inhibitor Opdivo, but that hasn’t ...

Rumours that Nektar Therapeutics may be talking about a merger with healthcare holding company PureTech have been confirmed by the two companies. UK-based PureTech – which develops its own ...

Research analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a note issued to investors on Wednesday, January 29th. Zacks Research ...

Nektar Therapeutics Stock Performance NASDAQ:NKTR opened at $0.89 on Friday. Nektar Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.93. The stock has a fifty day moving average of ...

Mark Andrew Wilson, the Chief Legal Officer at Nektar Therapeutics (NASDAQ:NKTR), recently sold shares of the company's common stock. According to a Form 4 filing with the Securities and Exchange ...